New weight-loss drug from Lilly surpasses Ozempic in effectiveness.
TL;DR Summary
Eli Lilly's experimental drug, retatrutide, which targets three hormones, led to 24.2% weight loss in a mid-stage trial, the greatest amount seen yet with an obesity drug. If the weekly injectable drug succeeds in larger Phase 3 trials, it could propel Lilly ahead of competitors in the heated race to supply the most effective obesity treatments.
- Ozempic 3.0? New weight loss drug from Lilly shows promise in Phase 2 trial STAT
- A new weight-loss drug dubbed the 'triple G' could be stronger than Ozempic, Wegovy, and Mounjaro — and as powerful as bariatric surgery Yahoo Life
- Yet Another Injectable Combo Achieves Near 15% Weight Loss in Trial Medpage Today
- Eli Lilly's New Weight-Loss Drug Is Even Better Than Ozempic Bloomberg
- Analysis | Eli Lilly's New Weight-Loss Drug Is Even Better Than Ozempic The Washington Post
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
1 min
vs 1 min read
Condensed
72%
197 → 56 words
Want the full story? Read the original article
Read on STAT